Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on January 27, 2017. The report details a material definitive agreement entered into on the same date regarding the amendment of existing warrant terms.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The financial impact is limited to the modification of warrant expiration dates without changes to exercise prices.
Material Changes
The Company amended two-year warrants issued in January and February 2015 to extend their expiration dates by two additional years. The exercise prices and all other original terms remain unchanged.
- Total Warrants Affected: 840,000 shares (420,000 at $3.00/share and 420,000 at $6.00/share).
- New Expiration Dates:
- 266,667 shares at $3.00 and 266,667 shares at $6.00 expire January 29, 2019.
- 140,000 shares at $3.00 and 140,000 shares at $6.00 expire February 10, 2019.
- 13,333 shares at $3.00 and 13,333 shares at $6.00 expire February 23, 2019.
Management Commentary and Risks
The amendment was executed with specific holders, including a subsidiary of IDT Corporation and entities controlled by Mr. Packer, both of whom are greater than five percent stockholders. The filing does not disclose specific risks, contingencies, or unusual items beyond the warrant extension itself.
Investor Verification Checklist
- Verify the total number of shares potentially issuable upon exercise of the amended warrants (840,000).
- Confirm the dilution impact of the extended warrants on existing shareholders.
- Review the relationship between the Company and the major warrant holders (IDT Corporation subsidiary and Mr. Packer).
- Check subsequent filings for any further amendments to the warrant terms or exercise activity.